NCT07298915Not yet recruitingPhase 3
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life Participants will: * Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- Aug 2026
- Primary completion date
- Dec 2026
- Lead sponsor
- University of Virginia
- Diseases
- Obesity
- NCT number
- NCT07298915
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 24
- From Aug 2026 to the primary completion date, Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of myocardial infarction or stroke
- Previous weight loss surgery
- Use of weight loss medication within the last year
Other illness
- Including but not limited to serious arrhythmias
- Congestive heart failure
- Stroke or transient ischemic attacks
- Peripheral vascular disease
- Hospitalization for mental illness within the past 5 years or currently undergoing treatment for severe mental illness
- Conditions that can be aggravated or are contraindicated by exercise training
Lab values
- Previous diagnosis or taking medication for type 1 or 2 diabetes, fasting glucose \>125 mg/dL or HbA1C ≥6.5%
Other
- Cardiomyopathy
- Systolic blood pressure \>160 mmHg and diastolic blood pressure \>100 mmHg.
- Plans to be out of town more than 3 weeks in the next 4 months.
- Currently pregnant or plans to become pregnant
- Currently in a diet or exercise program
- Non-compliance during screening or extreme difficulty in obtaining baseline blood samples
- Enrolled in a different exercise program
- hypo/hyper thyroid (medicated or unmedicated)
Who the study is looking for
- Men and women 30-65 years of age, postmenopausal women included
- 27-29.9 with an additional CVD risk factor or 30-40 kg/m2
- For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension)
- Willingness and adequate health to go on weight loss medication
- The capability and willingness to provide written informed consent
- Approval of their primary care provider to go on weight loss medication
Age in the registry: 30 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Virginia Coordinator of this site? Confirm its status | Charlottesville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.